Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
8
×
deals
8
×
eli lilly
8
×
life sciences
national blog main
national top stories
new york blog main
san diego blog main
san diego top stories
san francisco blog main
startups
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
pfizer
takeda pharmaceutical
alzheimer's disease
bristol-myers squibb
clinical trials
fda
investing
ipo
What
bio
roundup
drug
companies
drugs
pharmaceutical
buy
growing
nash
new
news
price
raise
typically
acquisitions
advance
alliance
alzheimer’s
appetite
approval
approved
bails
biggest
biogen’s
biology
biopharmaceutical
black
brand
bread
bridgebio
bristol
build
butter
buyout
calls
cancer
capital
car
cash
ceo
Language
unset
Current search:
deals
×
cancer
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs